Drug Trial Radar · NCT03056040
ALXN1210 Versus Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab
Last checked: Nov 20, 2026Latest source record: Mar 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
202
Actual
Start
May 17, 2017
Primary completion
Feb 21, 2022
Study completion Feb 21, 2022
Sponsor
- Lead sponsor
- Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Feb 16, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study was to assess the noninferiority of ravulizumab compared to eculizumab in adult participants with PNH who were clinically stable after having been treated with eculizumab for at least 6 months.
Conditions
- Paroxysmal Nocturnal Hemoglobinuria (PNH)
Interventions
RavulizumabBiological
All treatments were given as intravenous (IV) infusions. For participants weighing ≥40 to \<60 kilograms (kg): 2400 mg was given as a single loading dose, followed by 3000 mg as maintenance dose. For participants weighing ≥60 to \<100 kg: 2700 mg was given as a loading dose, followed by 3300 mg as maintenance dose. For participants weighing ≥100 kg: 3000 mg was given as a loading dose, followed by 3600 mg as maintenance dose.
EculizumabBiological
All treatments were given as IV infusions. Participants received 900 mg of eculizumab q2w.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change In Lactate Dehydrogenase Levels From Baseline To Day 183Time frame: Baseline, Day 183
Locations
51 sites in 11 countries. Site status is shown where the registry gives one.
Research Site
Duarte, California
Research Site
Los Angeles, California
Research Site
Baltimore, Maryland
Research Site
Detroit, Michigan
Research Site
The Bronx, New York
Research Site
Canberra, Australia
Research Site
Kogarah, Australia
Research Site
Liverpool, Australia
Research Site
Melbourne, Australia
Research Site
Woolloongabba, Australia
Research Site
Toronto, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Amiens, France
Research Site
La Tronche, France
Research Site
Marseille, France
Research Site
Nice, France
Research Site
Paris, France
Research Site
Pierre-Bénite, France
Research Site
Saint-Priest-en-Jarez, France
Research Site
Strasbourg, France
Research Site
Aachen, Germany
Research Site
Essen, Germany
Research Site
Ulm, Germany
Research Site
Florence, Italy
Research Site
Milan, Italy
Research Site
Naples, Italy
Research Site
Torino, Italy
Research Site
Vicenza, Italy
Research Site
Fukushima, Japan
Research Site
Kanazawa, Japan
Research Site
Shinagawa-ku, Japan
Research Site
Suita-shi, Japan
Research Site
Suwa-shi, Japan
Research Site
Maastricht, Netherlands
Research Site
Nijmegen, Netherlands
Research Site
Bucheon-si, South Korea
Research Site
Daegu, South Korea
Research Site
Daejeon, South Korea
Research Site
Incheon, South Korea
Showing 40 of 51 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.